Drug Trial Radar · NCT04786873
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Nov 16, 2021
Primary completion
Jun 13, 2024
Study completion Jun 13, 2024
Sponsor
- Lead sponsor
- AEterna ZentarisIndustry
- Sponsor type
- Industry
- First posted
- Mar 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study will find out if a new growth hormone stimulation test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children. The stimulation test will use a new growth hormone stimulating substance called macimorelin. By now, only adults in the USA can get this new stimulation test. The results of this study are expected to help children and teenagers with suspected GHD to get the macimorelin stimulation test. The macimorelin test will be compared to a clonidine and an arginine test. Both are known standard stimulation tests. Altogether two macimorelin tests are planned to be performed in the study, to show how repeatable macimorelin tests results are (under a set of similar conditions).
Conditions
- Growth Hormone Deficiency
Interventions
MacimorelinDrug
Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
ArginineDiagnostic test
For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
ClonidineDiagnostic test
For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg. After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the Receiver Operator Characteristic curve (ROC AUC) based on GH concentration during GHST following macimorelin administrationTime frame: Derived from Cmax GH measurements collected in the time frame from 0 to 90 minutes after initial macimorelin GHST (visit 2 (day 0)) and GH adjudication status performed by the adjudication committee after visit 4 (between day 11 and day 58)).
Locations
45 sites in 11 countries. Site status is shown where the registry gives one.
Angel Wing Clinic For Children With Diabetes
Tucson, Arizona
Pediatric Endocrine Associates, p.c.
Greenwood Village, Colorado
John Hopkins All Children's Hospital
St. Petersburg, Florida
Emory Healthcare-Children's Center
Atlanta, Georgia
St. Luke's Children's Endocrinology
Boise, Idaho
University of Minnesota, Masonic Children's Hospital
Minneapolis, Minnesota
The Children's Mercy Hospital - Broadway
Kansas City, Missouri
Icahn School of Medicine at Mount Sinai
New York, New York
Children's Hospital at Montefiore
The Bronx, New York
UNC Hospitals
Chapel Hill, North Carolina
Alchemi Research Center
Rosharon, Texas
Multicare Health System
Tacoma, Washington
Yerevan State Medical University after Mkhitar Heraci
Yerevan, Armenia
JSC Maritime Hospital
Batumi, Georgia
National Institute of Endocrinology
Tbilisi, Georgia
TSMU Givi Jvania Pediatric Academic Clinik
Tbilisi, Georgia
Evangelisches Klinikum Bethel
Bielefeld, Germany
Ospedale Pediatrico G. Salesi
Ancona, Italy
Azienda Ospedaliero-Universitaria Anna Meyer
Florence, Italy
Osp. dei Bambini V. Buzzi, ASST Fatebenefratelli Sacco
Milan, Italy
Azienda Ospedaliero-Universitaria di Parma Ospedale dei Bambini Pietro Barilla, Clinica Pediatrica
Parma, Italy
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, Italy
MED-POLONIA Sp.z o.o.
Poznan, Poland
Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie
Rzeszów, Poland
SPSK Nr 1 im. prof. Tadeusza Sokolowskiego PUM
Szczecin, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu
Wroclaw, Poland
Cen Med de Diagn si Trat Amb NEOMED
Brasov, Romania
Sana Monitoring
Bucharest, Romania
Medicover Hospitals
Bucharest, Romania
Institutul de Endocrinologie "C.I. Parhon"
Bucharest, Romania
Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei" Constanta
Constanța, Romania
Spitalul Clinic Judetean de Urgenta "Sf. Spiridon" Iasi
Iași, Romania
Spitalul Clinic Judetean Mures
Târgu Mureş, Romania
Spitalul Cl. de Urgenta pentru Copii Louis Turcanu Timisoara
Timișoara, Romania
University children's clinic Belgrade - Department of Endocrinology
Belgrade, Serbia
Clinical Center Nis - Clinic for Children's Internal Medicine
Niš, Serbia
Institute for Child and Youth Health Care of Vojvodina - Endocrinology
Novi Sad, Serbia
National Institute of Children's Diseases
Bratislava, Slovakia
Children's University Hospital Kosice
Košice, Slovakia
National Institute of Endocrinology and Diabetology
Ľubochňa, Slovakia
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.